【實用醫療app】AFib CDA|最夯免費app-綠色工廠好玩App

The availability of new antithrombotic agents, each with a unique efficacy and bleeding profile, has introduced a considerable amount of clinical uncertainty with physicians. We have developed a clinical decision aid that assists clinicians in determining an optimal antithrombotic regime for the prevention of stroke in patients who are newly diagnosed with non-valvular atrial fibrillation.This iPad Application allows physicians to accurately and efficiently estimate an individual patient’s baseline annual absolute risk of stroke and bleeding using the CHA2DS2-VASc and HAS-BLED scoring systems.The Clinical Decision Aid then identifies the antithrombotic agent that is associated with the lowest Net Risk to the patient, and recommends an optimal antithrombotic regime for the prevention of stroke based upon the patient’s particular CHA2DS2VASc and HAS-BLED Scores.